Webinar: HTA and Innovations in Healthcare
Thursday, Dec 09, 2021 From 10:00 to 11:30
Will the evaluation of the benefits of treatment in Slovakia approach the European standards?
Thank you for your interest to join AmCham webinar. Please, find the link below:
The topic of HTA (Health Technology Assessment) in the context of health innovation assessment is fundamental to the future of health system across Europe. Whilst the Individual HTA agencies vary in the way they approach healthcare innovation assessment as well as in their position within the health system across EU, the pressure to adapt the HTA processes is growing, as the agencies face new challenges. In the light of the newly created National Institute for Value and Technology in Healthcare, the topics of the HTA and innovation in healthcare are very important in Slovakia as well.
Offering a look into how experts in the field view the matter at hand as well as concrete principles of what needs to be done to bring a more value-based healthcare and improve the evaluation of innovative treatments in Slovakia, the event will serve to:
Highlight the relevance of an official HTA body in Slovakia:
- How can the topic of assessing innovation in healthcare be understood in the local context?
- How do experts perceive the establishing HTA agency in Slovakia – is it in their eyes a sensible development, also with regards to the proposed institutional set-up of the agency?
- Can we look for inspiration to the Czech Republic when setting up the HTA agency in Slovakia?
Discuss the role of patient organisations within HTA:
- Can patient-centric approach bear fruits in terms of improving patient access to modern treatment?
- Can the set-up of the agency in Slovakia embrace a patient-centric approach?
- What role does patient perspective play in the HTA processes in the Czech Republic?
Sketch an outlook for the future:
- How do the experts in the field perceive the future of the HTA agency in Slovakia?
- Can the HTA agency work in Slovakia and help the country come closer to the EU standards?
- Can the HTA agency bring a real, lasting, change for good of patients?
- PROF. RÓBERT BABEĽA, State Secretary, Ministry of Health of the Slovak Republic
- ALAN LOVELL, Information Services Manager, The Economist Intelligence Unit
- JANA HLAVÁČOVÁ, Head of Unit for Promotion of Pacients’ Rights, Ministry of Health of the Czech Republic
- MIROSLAVA FOVENYES, Innovation and patient advocacy Lead, Lymfoma a Leukémia Slovensko
- MÁRIA LÉVYOVÁ, President, The Association for the Protection of Patients’ Rights in Slovakia (AOPP)
- MAREK PSOTA, HTA expert, Slovak Republic
- TOMÁŠ DOLEŽAL, HTA expert, Czech republic
- ELENA MARUŠÁKOVÁ, Vice president, Association for the Protection of Patients’ Rights of the Slovak Republic
- ANNA MICHALKOVÁ, Member of the AmCham Board of Directors (Moderator)